We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+2.62%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$1.87B
AUM Growth
-$718M
Cap. Flow
-$858M
Cap. Flow %
-45.75%
Top 10 Hldgs %
41.84%
Holding
112
New
12
Increased
13
Reduced
41
Closed
27

Top Buys

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$30.8M
2
XENT
Intersect ENT, Inc
XENT
+$26.9M
3
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$19.7M
4
PDCO
Patterson Companies, Inc.
PDCO
+$17.7M
5
MCK icon
McKesson
MCK
+$13.1M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$49.3M
2
ELV icon
Elevance Health
ELV
+$43.6M
3
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$41.3M
4
DBVT
DBV Technologies
DBVT
+$36.8M
5
CNC icon
Centene
CNC
+$36.6M

Sector Composition

Rank Sector Weight
1 Healthcare 71.91%
2 Financials 1.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHC icon
76
Bausch Health
BHC
$1.8B
– –
-1,500,000
Closed -$16.5M
BLUE
77
DELISTED
bluebird bio
BLUE
– –
-8,265
Closed -$9.73M
CRVS icon
78
Corvus Pharmaceuticals
CRVS
$1.25B
– –
-36,931
Closed -$767K
EYPT icon
79
EyePoint Inc
EYPT
$1.12B
– –
-149,282
Closed -$2.57M
GMED icon
80
Globus Medical
GMED
$10.5B
– –
-308,000
Closed -$9.12M
HUM icon
81
Humana
HUM
$48B
– –
-69,185
Closed -$14.3M
SAGE
82
DELISTED
Sage Therapeutics
SAGE
– –
-122,000
Closed -$8.67M
SCYX icon
83
SCYNEXIS
SCYX
$42.4M
– –
-13,100
Closed -$2.89M
SNDX icon
84
Syndax Pharmaceuticals
SNDX
$2.02B
– –
-38,130
Closed -$523K
STRM
85
DELISTED
Streamline Health Solutions
STRM
– –
-44,198
Closed -$676K
TGTX icon
86
TG Therapeutics
TGTX
$8.4B
– –
-700,000
Closed -$8.15M
VNDA icon
87
Vanda Pharmaceuticals
VNDA
$327M
– –
-2,299,046
Closed -$32.2M
VTRS icon
88
CALL
Viatris
VTRS
$20.1B
– –
-450,000
Closed -$17.5M
WBA
89
DELISTED
Walgreens Boots Alliance
WBA
– –
-355,957
Closed -$29.6M
NSTG
90
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-352,375
Closed -$7M
INFI
91
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-1,969,225
Closed -$6.36M
MTEM
92
DELISTED
Molecular Templates, Inc.
MTEM
– –
-13,346
Closed -$1.25M
TVTY
93
DELISTED
Tivity Health, Inc. Common Stock
TVTY
– –
-76,000
Closed -$2.21M
FPRX
94
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-138,000
Closed -$4.99M
ONCE
95
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-283,000
Closed -$15.1M
ARRY
96
DELISTED
Array Biopharma Inc
ARRY
– –
-1,142,744
Closed -$10.2M
GNCA
97
DELISTED
Genocea Biosciences, Inc.
GNCA
– –
-59,875
Closed -$2.92M
CASM
98
DELISTED
CAS Medical Systems, Inc.
CASM
– –
-1,798,434
Closed -$2.61M
TSRO
99
DELISTED
TESARO, Inc.
TSRO
– –
-66,000
Closed -$10.2M
KITE
100
DELISTED
Kite Pharma, Inc.
KITE
– –
-81,000
Closed -$6.36M
1 2 3
4
5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q2 2017 Portfolio in Review

As of Q2 2017, Deerfield Management held 112 positions worth $1.87B, down 28% from $2.59B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Deerfield Management withdrew a net $858M in Q2 2017, closing 27 positions and reducing 41 holdings. Its most notable exit was Vanda Pharmaceuticals, an estimated $32.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 71% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Intersect ENT, Inc worth $33.2M.

  • Deerfield Management's largest Q2 2017 buy was Intersect ENT, Inc: 1,189,577 shares worth $33.2M.
  • Deerfield Management added most to Glaukos in Q2 2017, an estimated $30.8M increase.
  • Deerfield Management's biggest Q2 2017 reduction was Blueprint Medicines, cutting an estimated $49.3M.
  • Deerfield Management fully exited Vanda Pharmaceuticals in Q2 2017, selling an estimated $32.2M.
  • Deerfield Management's ten largest holdings make up 42% of its $1.87B portfolio in Q2 2017.
  • Deerfield Management opened 12 new positions and closed 27 in Q2 2017.
  • Deerfield Management's portfolio value fell 28% quarter-over-quarter to $1.87B.

Based on Deerfield Management's 13F filing for Q2 2017, filed 14 Aug 2017.